Safe and Sustained Overexpression of Functional Apolipoprotein A-I/High-density Lipoprotein in Apolipoprotein A-I–null Mice by Muscular Adeno-associated Viral Serotype 8 Vector Gene Transfer
暂无分享,去创建一个
V. Fuster | J. Badimón | C. Giannarelli | B. Ibáñez | G. Cimmino | R. Hajjar | W. Speidl | C. Walsh | Wei Chen
[1] S. Vaessen,et al. AAV gene therapy as a means to increase apolipoprotein A-I and high-density lipoprotein- cholesterol levels: Correction of murine apoA-I deficiency , 2009 .
[2] Z. Xiang,et al. A preclinical animal model to assess the effect of pre-existing immunity on AAV-mediated gene transfer. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.
[3] V. Fuster,et al. Up-regulation of reverse cholesterol transport key players and rescue from global inflammation by ApoA-IMilano , 2008, Journal of cellular and molecular medicine.
[4] J. Kira,et al. Transduction efficiency and immune response associated with the administration of AAV8 vector into dog skeletal muscle. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.
[5] Borja Ibanez,et al. HDL-cholesterol: is it really good? Differences between apoA-I and HDL. , 2008, Biochemical pharmacology.
[6] Michael Hallek,et al. Recent developments in adeno‐associated virus vector technology , 2008, The journal of gene medicine.
[7] P. Venkatesh,et al. Therapies to increase high-density lipoprotein cholesterol and their effect on cardiovascular outcomes and regression of atherosclerosis. , 2008, The American journal of the medical sciences.
[8] D. Yellon,et al. Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels , 2008, Postgraduate Medical Journal.
[9] T. Flotte,et al. Clinical gene therapy using recombinant adeno-associated virus vectors , 2008, Gene Therapy.
[10] M. Shakibaei,et al. Human Apolipoprotein A-I Gene Transfer Reduces the Development of Experimental Diabetic Cardiomyopathy , 2008, Circulation.
[11] Gemma Vilahur,et al. Rapid change in plaque size, composition, and molecular footprint after recombinant apolipoprotein A-I Milano (ETC-216) administration: magnetic resonance imaging study in an experimental model of atherosclerosis. , 2008, Journal of the American College of Cardiology.
[12] E. Fisher,et al. Atheroprotective effects of HDL: beyond reverse cholesterol transport. , 2008, Current drug targets.
[13] M. Caulfield,et al. Effects of torcetrapib in patients at high risk for coronary events. , 2007, The New England journal of medicine.
[14] D. Rader,et al. Gene transfer of wild-type apoA-I and apoA-I Milano reduce atherosclerosis to a similar extent , 2007, Cardiovascular diabetology.
[15] Colin Berry,et al. Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial. , 2007, JAMA.
[16] Zui Tan,et al. Adeno-associated virus vectors simultaneously encoding VEGF and angiopoietin-1 enhances neovascularization in ischemic rabbit hind-limbs , 2007, Acta Pharmacologica Sinica.
[17] J. Gray,et al. Safe and efficient transduction of the liver after peripheral vein infusion of self-complementary AAV vector results in stable therapeutic expression of human FIX in nonhuman primates. , 2007, Blood.
[18] J. Wilson,et al. Efficacy and safety of adeno‐associated viral vectors based on serotype 8 and 9 vs. lentiviral vectors for hemophilia B gene therapy , 2006, Journal of thrombosis and haemostasis : JTH.
[19] Z. Cao,et al. A comparative study of hFIX expression mediated by rAAV8 and rAAV1 administrated intramuscularly. , 2007, Cytotherapy.
[20] D. Rader,et al. Persistent liver expression of murine apoA-l using vectors based on adeno-associated viral vectors serotypes 5 and 1. , 2006, Atherosclerosis.
[21] H. Kazazian,et al. Long-term efficacy of adeno-associated virus serotypes 8 and 9 in hemophilia a dogs and mice. , 2006, Human gene therapy.
[22] D. Rader,et al. New Insights Into the Regulation of HDL Metabolism and Reverse Cholesterol Transport , 2005, Circulation research.
[23] Lili Wang,et al. Gene transfer into skeletal muscle using novel AAV serotypes , 2005, The journal of gene medicine.
[24] Theresa A. Storm,et al. Unrestricted Hepatocyte Transduction with Adeno-Associated Virus Serotype 8 Vectors in Mice , 2005, Journal of Virology.
[25] M. Hayden,et al. Long-term correction of murine lipoprotein lipase deficiency with AAV1-mediated gene transfer of the naturally occurring LPL(S447X) beneficial mutation. , 2004, Human gene therapy.
[26] Paul Schoenhagen,et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. , 2003, JAMA.
[27] A. Beaudet,et al. Long-Term Stable Expression of Human Apolipoprotein A-I Mediated by Helper-Dependent Adenovirus Gene Transfer Inhibits Atherosclerosis Progression and Remodels Atherosclerotic Plaques in a Mouse Model of Familial Hypercholesterolemia , 2003, Circulation.
[28] D. Collen,et al. Persistent hepatic expression of human apo A-I after transfer with a helper-virus independent adenoviral vector , 2002, Gene Therapy.
[29] Lili Wang,et al. Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[30] G. Blancho,et al. Immediate and long-term safety of recombinant adeno-associated virus injection into the nonhuman primate muscle. , 2001, Molecular therapy : the journal of the American Society of Gene Therapy.
[31] R. Samulski,et al. Sustained and complete phenotype correction of hemophilia B mice following intramuscular injection of AAV1 serotype vectors. , 2001, Molecular therapy : the journal of the American Society of Gene Therapy.
[32] R. Herzog,et al. Muscle-directed gene transfer and transient immune suppression result in sustained partial correction of canine hemophilia B caused by a null mutation. , 2001, Molecular therapy : the journal of the American Society of Gene Therapy.
[33] D. Collen,et al. Sustained expression of human apo A-I following adenoviral gene transfer in mice , 2001, Gene Therapy.
[34] R. Samulski,et al. Direct intramuscular injection with recombinant AAV vectors results in sustained expression in a dog model of hemophilia , 1998, Gene Therapy.
[35] P. Clarkson,et al. Variability in serum creatine kinase response after eccentric exercise of the elbow flexors. , 1996, International journal of sports medicine.
[36] V. Fuster,et al. Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit. , 1990, The Journal of clinical investigation.
[37] T D Noakes,et al. Effect of Exercise on Serum Enzyme Activities in Humans , 1987, Sports medicine.
[38] M C Hjortland,et al. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. , 1977, The American journal of medicine.